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Background and Objective: 
More than 30 percent of patients with epilepsy have inadequate control of seizures with drug therapy. The 
goal of this study is to determine the budget impact with a five year time horizon of the introduction of 
brivaracetam to the portfolio of approved drugs in Spain as adjunctive therapy for the treatment of partial 
onset epilepsy in patients over 16 years old in the Valencia Community, a Spanish region with a population 
of 5 million. 
Methods: 
The budget impact model compares the pharmaceutical expenditure on anti-epileptics in two scenarios, 
with and without brivaracetam. It assumes that the introduction of brivaracetam will increase proportionally 
to a decrease in consumption of coexisting adjunctive anti-epileptics and calculates the evolution of its 
consumption over five years (2016-2020). The model was designed from the perspective of the Spanish 
National Health System. Data on the candidate population, consumption of anti-epileptics, market share 
and pharmaceutical expenditure were obtained from real world data. Finally, a sensitivity analysis was 
carried out on the set of variables involved in the evolution of costs using a Monte Carlo simulation.  
Results: 
The model estimates that the target population eligible for adjunctive anti-epileptics will hold at around 
2,352 between 2016-2020. Annual expenditure on anti-epileptics is approximately 3.6 million Euros. The 
number of patients eligible for treatment with brivaracetam would increase from 42 to 179 and annual 
savings of 0.09-0.37% would be created, representing 41,873 Euros in five years (0.23% of the total). The 
sensitivity analysis corroborates that the probability of achieving savings with brivaracetam is around 84%.  
Conclusions: 
Brivaracetam is a therapeutic alternative that allows savings for the health system in non-controlled 
epileptic patients in monotherapy, having a fixed, predictable annual cost (independent of dose) from the 
first day of treatment, given that the patient is within a range of therapeutic doses without the need for prior 
titration.  
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Key points 
Brivaracetam is a new third generation anti-epileptic drug offering a new therapeutic alternative for 
concomitant therapy in the treatment of partial onset epileptic seizures, with or without secondary 
generalisation, in adults and adolescents above 16. 
The results from this budget impact analysis suggest that brivaracetam is a cost-saving therapeutic strategy 
for adjunctive therapy for epilepsy in Spain 
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1. Introduction  
Epilepsy is one of the most common chronic neurological diseases in the world, with the World Health 
Organisation estimating that it affects around 50 million people [1]. According a recent systematic review, 
prevalence of active epilepsy was 6.38 per 1,000 persons, while the lifetime prevalence was 7.60 per 1,000 
persons. The annual cumulative incidence of epilepsy was 67.77 per 100,000 persons while the incidence 
rate was 61.44 per 100,000 person-years [2]. 
There are two types of epileptic seizure, generalised seizures in which all the surface of the brain is affected 
at the same time, and partial onset or focal seizures which begin affecting one part of the brain [3, 4]. In 
Spain it is estimated that around 400,000 people are affected, with nearly 60% of patients having partial 
onset or focal seizures [4]. 
Anti-epileptic treatment centres on the greatest reduction of the number of epileptic seizures, while 
minimising adverse effects and long-term toxicity as far as possible. Clinical evidence shows that 
monotherapy with anti-epileptic drugs (AEDs) is effective in 70% of patients [5]. The remaining 30% need 
adjunctive treatment to control the seizures [6] and, of these, approximately 25% have epilepsy that is 
difficult to control, refractory or resistant to AEDs. This implies difficulty in its management for the 
neurologist and the need to study other treatment strategies or optimise available pharmacological 
treatments. The importance of refractory epilepsy is in the significant decrease in quality of life with, 
moreover, the presence of associated morbidities (depression being the most frequent) and increased 
probability of early death compared to patients with controlled epilepsy [7, 8]. 
The annual direct cost of epilepsy in Spain is estimated to be 2,978 Euros/patient in the case of controlled 
epilepsy and between 4,964 [9] and 6,935 [4] Euros/patient for non-controlled, that is, between 1.7 and 2.3 
times greater than with controlled patients. This proportion reaches 2.7 times greater in infantile 
epilepsy[3]. Furthermore, non-controlled epilepsy is associated with a greater consumption of health care 
resources, lower quality of life and a greater incidence of severe depression. Therefore, it places a 
considerable burden on the National Health Service and society, as severe levels of anxiety and depression 
are associated with very high costs for the health system [10]. 
 
The neurologist has more than 20 AEDs available for the treatment of epilepsy, some of which have 
numerous side effects and interactions that can complicate patient treatment and management, especially 
for those with refractory epilepsy [5]. Since 1993, more than 12 new AEDs have been approved that have 
an effect on seizure control and a better tolerability profile, as well as a lower risk of drug interactions. To 
the 4 classic or first generation AEDs (phenobarbital, phenytoin, carbamazipine and sodium valproate), 8 
second generation (gabapentin, oxcarbazepine, topiramate, lamotrigine, vigabatrin, pregabalin, tiagabine 
and levetiracetam) and 5 third generation (retigabine, eslicarbazepine, lacosamide, perampanel and 
zonisamide) AEDs have been added. Nevertheless, 30% of patients are not entirely controlled [6, 11]. 
The choice of the most suitable AED depends principally on the patient's type of epilepsy, on the 
effectiveness and on the individual profile for tolerability and adverse effects. Generally, the new drugs are 
better tolerated, though not always more effective [12]. When comparing treatments, it is important to 
compare: 1) drugs with the same indication (in this case, adjunctive drugs for partial onset seizures,); 2) the 
need for titration and duration of this (speed in stabilising patient); 3) available pharmaceutical forms for 
different clinical situations; 4) dosage (which will influence in long-term compliance); 5) 
cost/treatment/day  (affordable for the health service); 6) efficiency and effectiveness in real life; 7) safety 
and interactions profile (associated with being a 1st, 2nd or 3rd generation drug). 
Brivaracetam is a new third generation AED offering a new therapeutic alternative for concomitant therapy 
in the treatment of partial onset epileptic seizures (POS), with or without secondary generalisation, in adults 
and adolescents above 16 years of age. This drug was approved by the European Medicines Agency in 
January 2016 [13]. Unlike other AEDs, it has a fixed cost, independent of dosage and has no need for 
titration ensuring the patient is within a therapeutic dosage range from the first day. It has a good tolerability 
profile and is commercialised in all the pharmaceutical forms to deal with different patient profiles (out-
patients and hospitalised ) [14, 15]. 
When introducing a new medicine to the existing portfolio for a disease, the budget impact analysis (BIA) 
for the new medicine is an important tool in helping to take decisions. A BIA is implemented to assess the 
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sustainability of the use a new technology, in this case a new drug.  As such, the goal of this study was to 
determine the budget impact of the introduction of brivaracetam to the portfolio of approved drugs in Spain 
as adjunctive therapy for the treatment of POS in patients over 16 years of age with a five year time horizon 
in the Valencia Community (VC), a Spanish region with a population of 5 million. 
2. Material and methods  
2.1 Design 
The BIA model was based on the latest methodological recommendations proposed by the International 
Society for Pharmacoeconomics and Outcomes Research (ISPOR) principles on good practice for BIA [16]. 
The model estimates the incremental budget impact of adopting brivaracetam as a treatment for POS, and 
is structured in six basic steps for estimating budget impact: 1) estimating the target population; 2) selecting 
a time horizon; 3) identifying current and projected treatment mix; 4) estimating current and future drug 
costs; 5) estimating change in disease-related costs; and 6) estimating and presenting changes in annual 
budget impact. 
The starting point is the current market share of other AEDs in VC, obtained from real word data from the 
regional electronic prescribing system. The model simulates brivaracetam entering the market and drawing 
a market share in pre-defined proportions from the other available therapies. Therefore, if in year 1 
brivaracetam is assumed to reach 1.77 % market share, the model simulates what proportion of 
brivaracetam’s 1.77 % is drawn from each of the other replacement therapies. This is due to the particularly 
difficulty of establishing a market share in indications such as POS, given how many drugs are used in 
combination and the difficulty in obtaining market share data for the specific patient population (Figure 1). 
The assumptions and choices for the model are: 1) all patients in year 1 are assumed to be a mix of incidental 
and prevalent patients; 2) the model does not take into account any treatment switch due to any reason; 3) 
patients are assumed to be 100% compliant to each regimen they receive; 4) for all adjunctive lines it is 
envisaged that when brivaracetam is introduced, the market share may grow over time, therefore the 
treatment mixes for the mix with brivaracetam can be adjusted from year 1 to year 5; 5) the safety profile 
of AEDs is considered similar. 
The growth rate was calculated assuming an annual population increase of 0.05%, according to data from 
the National Statistics Institute (INE) 2016, and a mortality of 1.9%[4] from available data in 2013. 
The third generation drugs included in this comparison are those that, according to their summary of product 
characteristics (SmPC), have the same indications as adjunctive for POS, with or without secondary 
generalisation, that is: lacosamide [17], eslicarbazepine [18], perampanel [19] , retigabine [20] and 
zonisamide [21] (Table 1). Retigabine was withdrawn from the market in June 2017, but is nevertheless 
included as it was commercially available at the time of the study (January 2016). 
The model was constructed using Microsoft Excel and based on the international recommendations for 
evaluations of this kind [16]. 
 
2.2 Estimating the target population 
The target population was: patients over 16 years of age diagnosed with epilepsy and taking AEDs, both in 
monotherapy and as adjunctive treatment. This was extracted from the database of the Valencian Health 
Department (Generalitat Valenciana), which registers all holders of a health card for 2013. These data were 
anonymised and we selected the following variables per patient: age, gender, ICD-9-CM Diagnosis Codes, 
drug dosage by ATC code and pharmaceutical expenditure. 
To avoid selecting any patient who was being treated with AEDs for diseases other than epilepsy, the 
following ICD-9-CM diagnoses related to epilepsy were selected: 345.90, 345.10 and 345.50 and cross-
checked with the data for drug consumption corresponding to AEDs with ATC codes N03AA, N03AB, 
N03AD, N03AE, N03AF, N03AG and N03AX.  
The patients who suffer from POS, with or without secondary generalisation, were estimated from existing 




2.3 Perspective and time horizon  
The budget impact is determined from the perspective of the health service of the VC with a time horizon 
of five years, from 2016 to 2020.  
 
2.4 Estimating AED market share and treatment mix 
To obtain the market shares, the consumption data for AEDs was crossed with the diagnoses of epilepsy in 
order to extract drug consumption for uses other than epilepsy. 
Table 2 shows the total market share of each AED for treating epilepsy. The first column shows the total 
market share for each AED, the second the percentage of each AED used as monotherapy, the third column 
shows the percentage of each AED used as adjunctive treatment and the last column gives the total annual 
pharmaceutical expenditure. 
The total pharmaceutical expenditure on AEDs was 15,342,650 Euros, with the AEDs included in the model 
accounting for 32.33% of the total (4,960,118 Euros) with a share of 9.78%. The percentage of patients in 
monotherapy was 3.25% (447 patients) and those treated with adjunctive therapy 14.10% (2,395 patients). 
The market shares are adjusted to the treatment of partial onset seizures with the AEDs introduced into the 
model as adjunctive therapy. The simulation of how the market share varies on the introduction of 
brivaracetam is shown in Table 3. 
To estimate the initial market share of brivaracetam, the patients considered eligible for treatment with 
brivaracetam were those not controlled by the other therapies (Table 2). The model simulates the entry of 
brivaracetam on the market with a predefined share which is extracted from the other available therapies 
and proportional to their share. This approach was adopted in order to reduce the work of compiling data 
on the present market share of all the relevant substitute therapies. Table 3 shows the number of patients 
there would be for each of the five years in each therapy. 
 
2.5 Estimate of costs 
The base year for the costs considered in the model is 2016. To calculate the average daily costs for each 
drug, data was used from the Ministry of Health, Social Services and Equality (Ministerio de Sanidad 
Servicios Sociales e Igualdad) [22] and BOT-PLUS [23], taking the ex-factory price. 
All AEDs except brivaracetam have a titration phase on initiating the treatment, varying between several 
days and several weeks. During this phase treatment is not effective, as the dose is gradually increased daily 
until it reaches the effective dose. The costs associated with this titration for each drug must be reflected in 
the model and were calculated from the dosage scale given in the approved SmPC for each over the time 
period established to reach the effective treatment dose [24]. These titration costs have been distributed 
over the five years of the study.  
The average daily costs of the maintenance phase for each AED were calculated according to the average 
daily dosage, which includes all the drugs included in the model having the same indications as 
brivaracetam. The dose considered was that stated in the SmPC. In accordance with the ISPOR guidelines 
[16], costs were considered with a discount rate of 0%, for the base case. Table 4 shows the 
cost/treatment/day for each AED for the average dose considered and the additional cost of the initial 
titration phase.  
The average daily cost of monotherapy treatment must also be added to the adjunctive treatment cost for 
each patient. This cost is calculated as an average of the most common therapies (carbamazipine, 
lamotrigine, oxcarbazepine, topiramate and valproate).  
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Dosage and frequency for the drugs is based on the SmPC of each product [13]. The pharmacological cost 
of the therapies studied is tied to the delivered dose. The number of days of treatment considered is 365 per 
year. 
Costs not related to the drugs, such as medical visits, hospital admissions and emergencies have not been 
included in the BIA, which is limited only to the costs of the adjunctive anti-epileptic drugs. 
 
2.6 Sensitivity analysis 
In order to analyse the robustness of the results, a sensitivity analysis was carried out with regard to those 
parameters of the model considered to have greater uncertainty associated with the values used in the base 
case [25]. 
A one-way sensitivity analysis of the budget impact (BI) was performed for the cost variation of the daily 
dosage of brivaracetam (alternative 1), and for increasing the brivaracetam market share by 10% 
(alternative 2), keeping the other variables constant. 
Additionally, a probabilistic sensitivity analysis (PSA) was performed. In a Monte Carlo simulation, 1,000 
interactions were carried out in which multiple variables introduced into the BIA varied simultaneously. 
The cost of the daily dose behaved as a random variable of normal distribution with an average price of 4 
Euros and a typical deviation of 5% of the average (0.2 Euros), being able to adopt any value belonging to 
the distribution. Effectiveness randomly varied between 50% and 100%. Market share followed the random 
values of normal distribution with an average from initial values and a typical deviation of 5% of the 
average. Discount rate varied randomly between 0% and 3%. 
From the Monte Carlo simulation we obtain the average BI and standard deviation and the cumulative 
probability distribution to establish the probability of a negative (savings) or positive (increased cost) BI.  
3. Results 
3.1 Market size 
In 2013 there were 4,714,840 people registered with a health card out of a VC population of 4,931,281. Of 
these, 82.58% (3,893,421) were over 16 years old. 26,972 had a diagnosis of epilepsy (50.8% men), with 
an average age of 51.32. Therefore, the percentage of patients with epilepsy among those over 16 years old 
in the in the VC for that year was 0.69%.  
Given the prevalence of partial onset epilepsy is 60% [3], from the total of patients diagnosed with epilepsy 
the approximate number of patients with partial onset epilepsy will be 16,183, and of these a total of 15,015 
will be prevalent and 1,168 incidental. 
Only 22,676 (84%) of the patients diagnosed with epilepsy in the database took AEDs for treatment and, 
as such, this study is centred on this 84%. Of these patients, 61.9% are treated with monotherapy (14,035) 
and 38.1% with adjunctive treatments (8,641). 
The potential population for treatment with brivaracetam are those patients using adjunctive treatments. Of 
the 8,641 patients being treated with adjunctive therapy, 14.10% (2,395) take one of the AEDs considered 
in the BIA model. 
For the first year studied (2016), the model is based on a population of 2,352 patients, the result of 
extrapolation from the population of 2013 to 2016, according to the population growth and mortality data 
considered. 
3.2 Pharmaceutical expenditure  
The model presents results for the annual cost per patient, calculated from both the titration phase (only 
attributable to the first year) and maintenance (average dose for the following years). 
Table 5 shows the evolution of the total daily costs of the medicines according to the evolution of the 
patients and the market share of each of the treatments. The amount according to the number of patients 
who follow each treatment (Table 3) is calculated for each year from the daily unit cost.  
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Brivaracetam titration costs are zero, as it can be initiated with an effective dosage, while the other AEDs 
have the additional costs shown in Table 5.  
Supposing for the base case that the share of brivaracetam increases from 1.77% to 7.59% in five years 
(Table 3), the drug with the greatest displacement would be lacosamide, which would lose a market share 
of 2.32%, due to the way in which the calculations of drug displacement were made according to their 
initial market share. 
3.3 Budget impact 
The population of the VC suffering from POS and eligible to take brivaracetam was 2,352 patients in 2016 
and is expected to stay more or less constant until 2020. Assuming the market share will increase linearly 
with time. Table 6 shows the total cost of medication in the reference scenario (without brivaracetam) and 
the new scenario (with brivaracetam). 
In the reference scenario the total cost of the medication is estimated at 3.608 million Euros in the first 
year, increasing to 3.615 million Euros in the fifth year (up 0.20%), while in the new scenario the total 
cost would hardly vary in the five years (Figure 2). 
In Table 6, it can be seen that the budget impact estimated as the difference between both scenarios is 
negative, thus representing a saving, and the absolute value is increased from 3,085 to 13,257 Euros. Over 
the total of the five years of the study, the introduction of brivaracetam on the market entails savings of 
41,873 Euros, that is, 0.23% of the total budget. Savings from lower acquisition costs is 85.12% of the total 
and savings for reduced titration costs is at 14.9%. 
3.5 Sensitivity analysis 
Table 7 shows the result of a one-way sensitivity analysis. A 1% decrease of the daily dosage cost of 
brivaracetam implies an increase in budget savings of 19.7%, with the percentage of savings on the initial 
budget being 0.28% for a five-year time horizon, that is, 0.05% greater than in the base case. An increase 
in cost of 1% would produce the opposite effect.  
A variation of 10% greater than in the base case in the introductory market share of brivaracetam would 
result in 10% budget savings, with the percentage in savings on the initial budget being 0.26%, that is 0.02% 
greater than in the base case. 
 
In the PSA we obtained a pattern of normal distribution of BI with an average of -33,719 Euros and a 
standard deviation of 33,844 Euros. The probability that the BI entails a saving for the National Health 
Service is 84%, which corroborates the robustness of the analysis with the probability obtained in these 
results (Figure 3). 
 
4. Discussion 
The BIA compares the scenario with and without brivaracetam, taking into account the population eligible 
for treatment with brivaracetam, the market shares of other adjunctive treatments and their variation on 
linearly introducing brivaracetam. 
The budget impact is conditioned by the displacement power of brivaracetam, which may be different to 
that considered and reflects an increasingly large budget saving from 0.09% in 2016 to 0.37% in 2020, an 
annual increasing average of 0.07%. Furthermore, the displacement of the other existing AEDs takes place 
in function of their initial market share, due to which the most used will also be the most displaced in the 
model. 
The source is a real life database of AED consumption for epilepsy in the VC, with the correct figures for 
the adult population with health card and the prevalence of epilepsy, as well as present consumption of 
different drugs on the market. The prevalence obtained was 0.69% of the adult population. The percentage 
of patients being treated by monotherapy is 61.89%, which is different from other national data of 70%. 
The results obtained for the VC can be extrapolated for the national population, in which there were 47,155 
adult patients with partial onset epilepsy in 2016, to give savings of 824,431 Euros over five years. This 
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estimate of the target population for the whole of Spain was taken from 80% of the national population 
being over 16 and epidemiological data from the literature, and not from real data on disease burden. 
Therefore, this BIA shows that the gradual introduction of brivaracetam in the VC creates a saving in the 
health service budget, with the amount depending fundamentally on the estimates used concerning the 
brivaracetam market share, costs and market penetration throughout a five year time horizon. 
In the base case, average global savings are estimated to be 41,873 Euros in five years, which is 0.23% of 
the cost attributable in this period to anti-epileptic therapies in patients with partial onset seizures in 
adjunctive treatment. 
The savings in titration become increasingly relevant in the period considered, as the titration costs of 
brivaracetam are equal to zero, while the therapies with the other AEDs it would replace are always positive. 
In the first year of the analysis, therapy using brivaracetam can create a positive BI, though these additional 
costs are compensated by the savings in titration costs over the following years. Effectively, this lack of 
need for titration together with its fixed cost in treatment/day (independent of dosage) are two of the reasons 
that would justify the potential savings associated with use of brivaracetam. 
The budget savings obtained could be even greater, due to the treatment-day cost of brivaracetam being 
established at 4.00 Euros, independently of the dose used. Therefore patients who need to increase their 
dose/day would cost the health system the same and it would help in controlling very refractory patients. 
Any increase in dose of the other co-adjunctive AEDs considered would, by contrast, bring with it an 
increase in the treatment/day cost. This effect helps decision-making regarding health management, as the 
BI would not be affected by a change of dosage of brivaracetam for a specific situation. 
The majority of the limitations ascribable to the use of assumptions have been dealt with by the sensitivity 
analysis carried out to test the robustness of the model and to determine the impact on the final result of 
changes in the most sensitive variables. Nevertheless, there are other kinds of limitations in the model where 
uncertainty could not be reduced and these must be taken into account: 
It is a future projection model of the use of a drug based on multiple assumptions and on the attitude of 
clinicians to the introduction of brivaracetam to the AED market. If this attitude is different to the expected, 
the brivaracetam market share could be different to that analysed in this study. Nevertheless, the sensitivity 
analysis shows that even with significant variation in the expected market share, the savings for the health 
service remain important. 
 
Only the costs of the medication were included, which implies the analysis does not take into account other 
associated health costs, such as medical visits, etc. The results of the BIA presuppose, therefore, that these 
other costs are similar for any other scenario, nor does it incorporate other supposed savings regarding costs 
of admissions or emergencies [26]. Nevertheless, these savings would be shared between all the AEDs 
proportionally to their market share. 
The dosages considered in the base model could be underestimating the average real dosages being used 
by the patients. In this case, the BIA obtained in the base case corresponds to a conservative scenario and 
the savings could be greater.  
The assumptions that the effectiveness of brivaracetam is 100%, the discontinuation rate is 0%, compliance 
is 100%, and that all patients remain to the end of the treatment, imply a certain removal from clinical 
reality. Nevertheless, for the purpose of the BIA, this supposition is neutral, as it applies equally to all the 
drugs considered.  
The assumption that there will be no dosage increase for any drug throughout the five years of the analysis 
is unrealistic in clinical practice, especially with certain drugs. This would, however, contribute to greater 
savings in the BIA. 
We believe that these effects compensate each other and that, therefore, the figures we reach in our analysis 
show the real range of savings for the Spanish Health Service supposed by the introduction of brivaracetam. 
The analysis is sufficiently robust and shows savings for important variations of the parameters introduced 
in the analysis, given that the Monte Carlo simulation shows the probability for savings is 84%, even when 
the parameters introduced in the analysis vary.  
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Having therapeutic alternatives available contributes to the sustainability of the health service, as well as 
increasing possibilities for treatment for patients and for the health service professionals. As such, 
brivaracetam is a therapeutic alternative that will provide savings to the health service for non-controlled 
epileptic patients in monotherapy [14, 15]. 
5. Conclusions 
The budget impact shows that the introduction of brivaracetam on the market provides savings in costs, due 
in part to the lowering of acquisition costs, given that the price of brivaracetam is less than other drugs with 
a high present market share, and also because of the decrease in titration costs in the scenario with 
brivaracetam. 
Even with the limitations mentioned above, the analysis concludes that the use of brivaracetam in the 
Valencian market in patients who do not show a suitable response to conventional AEDs could produce net 
savings of 41,873 Euros in five years.  
Based on these savings, regional and national health services should promote the choice of rational and 
cost-effective therapeutic strategies, fundamentally in chronic conditions such as epilepsy, which ensure 
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Table 1. List of selected comparators according to indication  
Anti-epileptic Indication Dosage 
Nº days 
titration 

















K + channel  
activation 
Tablets 




















Na + channel  
inhibition 
Tablets 














































Mg: milligrams; DS: data sheet; * Withdrawn from market in June 2017 
Compiled from data published in authorised summary of product characteristics. Spanish Agency of 
Medicines and Medical Devices (AEMPS) 
** Lacosamide and brivaracetam may be used intravenously in special hospital clinical situations, such as 
status epilepticus or surgical operations. Dosage is variable. 
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Table 2. Market share of AEDs and pharmaceutical expenditure in VC: % Market share, % patients in 
monotherapy and % patients in add-on treatment. 
AED Market Share % 
% in 
monotherapy % add-on 
 Pharmaceutical 
expenditure (€) 
Carbamazepine 8.3 9.3 7.6 132,667  
Clonazepam 6.4 2.1 9.2 46,449 
Ethosuximide 0.1 0.0 0.2 7,332  
Phenobarbital 4.2 2.1 5.6 34,542  
Phenytoin 5.8 5.3 6.1 49,476  
Primidone 0.5 0.4 0.6 13,466  
Valproic acid  16.3 20.2 13.8 641,081  
Valpromide 0.1 0.1 0.1  1,816  
Total classic 41.7 39.5 43.2 926,829  
AED Market Share % 
% in 
monotherapy % add-on 
 Pharmaceutical 
expenditure (€) 
Gabapentin 3.1 3,0 3.2 132,421  
Lamotrigine 10.1 11.4 9.3 1,105,525  
Levetiracetam 24.3 34,0 18,0 6,639,228  
Oxcarbazepine 3.5 4.1 3.1 286,374  
Pregabalin 3.5 1.8 4.7 686,281  
Rufinamide 0.1 0.0 0.1 83,987  
Tiagabine 0.1 0.0 0.2 24,159  
Topiramate 3.8 3,0 4.3 521,887  
Vigabatrin 0.1 0.0 0.2 26,620  
Total 2nd generation 48.6 57.3 43.1 9,506,482  
AED Market Share % 
% in 
monotherapy % add-on 
 Pharmaceutical 
expenditure (€) 
Eslicarbazepine 2.5 1.3 3.3 1,408,626  
Lacosamide 3.6 0.9 5.5 1,937,087  
Perampanel 1.0 0.0 1.6 399,520  
Retigabine 0.1 0.0 0.2 32,825  
Zonisamide 2.3 0.9 3.2 1,131,281  
Total 3rd generation 9.5 3.1 13.8 4,909,339  
Total 100 100 100 15,342,650  
 
* Valencian Health Authority, Electronic Prescription System. 2014. Prescriptions for epilepsy diagnoses 
only. 
** Patient with two or more add-on AEDs combined. 
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Table 3. Initial market share and estimated variation for the following years.  
AED 
Market Share 
 3rd Generation 
Adjusted to 
100% 2016 2017 2018 2019 2020 
% % Patients % Patients % Patients % Patients % Patients % 
Eslicarbazepine 3.28 23.91      553    23.50       544    23.1       536    22.8       528    22.41       521    22.1 
Lacosamide 5.46 39.80      919    39.08       905    38.4       891    37.8       878    37.26       867    36.8 
Perampanel 1.59 11.59      267    11.36%       263    11.2       259    11.0       255    10.84       252    10.7 
Retigabine 0.20 1.46        34    1.45         34    1.4         33    1.4         33    1.38         32    1.4 
Zonisamide 3.19 23.25      537    22.83       528    22.5       520    22.1       513    21.77       506    21.5 
Brivaracetam            42    1.77         80    3.4       116    4.9       149    6.34       179    7.59 
  13.72 100   2,352    100    2,353    100    2,354    100    2,355    100    2,357    100 
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Table 4. Cost of drugs and titration  
AED Cost/treatment/day (€)* Titration phase cost (€) 
(Average daily dose) 
 
 
Zonisamide       
(400mg/day) 
3.55  51.72  
Perampanel       
(8mg/day) 
3.78  186.48  
Retigabine         
(900mg/day) 
3.80  106.56  
Brivaracetam    
(independent of dose) 
4.00  NA 
Lacosamide        
(300mg/day) 
4.48  31.38  
Eslicarbazepine 
(800mg/day) 
4.48  31.36  
Average cost of 
concomitant monotherapy 
0.60    
* Ex-factory price 








Daily cost/unit (€) 2016 (€) 2017 (€) 2018 (€) 2019 (€) 2020 (€) 
Eslicarbazepine 
acetate  
4.48 2,476 2,437 2,400 2,365 2,334 
Lacosamide 4.48 4,118 4,052 3,990 3,932 3,882 
Perampanel 3.78 1,010 994 979 965 952 
Retigabine 3.8 130 128 126 124 122 
Zonisamide 3.55 1,906 1,876 1,847 1,820 1,797 
Adjunctive 
therapies 
Titration costs (€) 2016 (€) 2017 (€) 2018 (€) 2019 (€) 2020 (€) 
Eslicarbazepine 
acetate  
31.36 3,467 3,412 3,360 3,311 3,268 
Lacosamide 31.38 5,769 5,677 5,590 5,509 5,438 
Perampanel 186.48 9,968 9,809 9,659 9,518 9,396 
Retigabine 106.56 727 715 704 694 685 
Zonisamide 51.72 5,554 5,465 5,382 5,303 5,235 
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Table 6. Summary of results 
 
Budget forecast without 
brivaracetam 
2016 2017 2018 2019 2020 
Acquisition costs (€) 3,582,066 3,583,857 3,585,649 3,587,442 3,589,235 
On initiation of AED (titration) (€) 25,943 25,956 25,969 25,982 25,995 
Total w/o brivaracetam (€) 3,608,009 3,609,813 3,611,618 3,613,424 3,615,231 
Budget forecast with brivaracetam 
2016 2017 2018 2019 2020 
Acquisition costs (€) 3,579,440 3,578,839 3,578,356 3,578,021 3,577,951 
On initiation of AED (titration) (€) 25,484 25,079 24,694 24,335 24,022 
Total with brivaracetam (€) 3,604,924 3,603,918 3,603,051 3,602,356 3,601,974 
BUDGET IMPACT 
2016 2017 2018 2019 2020 
Acquisition costs (€) -2,626 -5,017 -7,292 -9,421 -11,284 
On initiation of AED (titration) (€) -459 -877 -1,275 -1,647 -1,973 




Table 7. Brivaracetam Budget Impact, Base-case, and Alternative Analyses in Euros 
 
  BI 
Base case (€) 
  
Alternative Scenario 1 
Daily cost of brivaracetam 
1% lower (€) 
Alternative Scenario 2 
Market shares rises 10% 
(€) 
BI without 
brivaracetam 18,058,095 18,058,095 18,058,095 
With 
brivaracetam 18,016,222  18,007,974  18,012,035  
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Figure 3. Cumulative probability  
 
 
 
